AU2013276950B2 - Protein expression analyses for identifying genotoxic compounds - Google Patents

Protein expression analyses for identifying genotoxic compounds Download PDF

Info

Publication number
AU2013276950B2
AU2013276950B2 AU2013276950A AU2013276950A AU2013276950B2 AU 2013276950 B2 AU2013276950 B2 AU 2013276950B2 AU 2013276950 A AU2013276950 A AU 2013276950A AU 2013276950 A AU2013276950 A AU 2013276950A AU 2013276950 B2 AU2013276950 B2 AU 2013276950B2
Authority
AU
Australia
Prior art keywords
genotoxic
proteins
compounds
protein
expression levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013276950A
Other languages
English (en)
Other versions
AU2013276950A1 (en
Inventor
Yasmin DIETZ
Stefan Otto MUELLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2013276950A1 publication Critical patent/AU2013276950A1/en
Application granted granted Critical
Publication of AU2013276950B2 publication Critical patent/AU2013276950B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2013276950A 2012-06-13 2013-05-28 Protein expression analyses for identifying genotoxic compounds Ceased AU2013276950B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659024P 2012-06-13 2012-06-13
US61/659,024 2012-06-13
PCT/EP2013/001575 WO2013185884A1 (en) 2012-06-13 2013-05-28 Protein expression analyses for identifying genotoxic compounds

Publications (2)

Publication Number Publication Date
AU2013276950A1 AU2013276950A1 (en) 2015-01-29
AU2013276950B2 true AU2013276950B2 (en) 2018-07-26

Family

ID=48536789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013276950A Ceased AU2013276950B2 (en) 2012-06-13 2013-05-28 Protein expression analyses for identifying genotoxic compounds

Country Status (9)

Country Link
US (1) US20150140123A1 (enExample)
EP (1) EP2861985B1 (enExample)
JP (1) JP6301915B2 (enExample)
CN (1) CN104364649B (enExample)
AU (1) AU2013276950B2 (enExample)
CA (1) CA2876402A1 (enExample)
ES (1) ES2660131T3 (enExample)
IL (1) IL236195B (enExample)
WO (1) WO2013185884A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9470694B2 (en) 2013-03-09 2016-10-18 Litron Laboratories Ltd. Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations
US11513125B2 (en) * 2013-03-14 2022-11-29 Pioma, Inc. Microvesicle histone H2AX as a biomarker for genotoxic stress
CN104515760B (zh) * 2014-12-17 2017-10-31 深圳市纳观生物有限公司 双色荧光定位超分辨率生物显微方法及系统
WO2017145816A1 (ja) * 2016-02-24 2017-08-31 ソニー株式会社 光学測定器、フローサイトメータ、および放射線計数器
CN107159327B (zh) * 2017-05-17 2019-04-19 京东方科技集团股份有限公司 一种生物检测芯片及其检测方法
CN110333207A (zh) * 2019-06-25 2019-10-15 中国人民解放军陆军军医大学第一附属医院 CREB在Ang-2调节VEGFR2表达中分析方法
WO2021102420A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Interferon signaling as a cancer biomarker
CN112680498A (zh) * 2020-12-28 2021-04-20 华南理工大学 一种遗传毒性物质的高通量筛查方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411198D0 (en) * 2004-05-20 2004-06-23 Gentronix Ltd Genotoxic testing
ATE480642T1 (de) * 2004-11-24 2010-09-15 Hoffmann La Roche Verfahren zur bestimmung von genotoxizität
JP2011505847A (ja) * 2007-12-20 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 遺伝毒性の予測方法
GB0905410D0 (en) * 2009-03-28 2009-05-13 Gentronix Ltd Genotoxicity testing
DE102010024898B4 (de) * 2010-06-24 2012-10-25 Merck Patent Gmbh Genexpressionsanalysen zur Charakterisierung und Identifizierung genotoxischer Verbindungen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHOU, W-W., ET AL., "Arecoline-Induced Phosphorylated p53 and p21WAF1 Protein Expression is Dependent on ATM/ATR and Phosphatidyl-3-Kinase in Clone-9 Cells",(Journal of Cellular Biochemistry, Vol.107, No.3, 2009, pages 408-417 *
Liang, X., ET AL., "The Role ofWild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of PlatinumResistance with a Chk2 Inhibitor.", Chemotherapy Research and Practice, 2011, Article 715469 [online] *
MALMLOF, M., ET AL, "Mdm2 as a Sensitive and Mechanistically Informative Marker for Genotoxicity Induced by Benzo[a]pyrene and Dibenzo[a,l]pyrene", TOXICOLOGICAL SCIENCES, (2007-10-18), vol. 102, no. 2, pages 232 - 240 *
PALII, S.S., ET AL., "DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide ...", MOLECULAR AND CELLULAR BIOLOGY, 2007, vol. 28, no. 2, pages 752 - 771 *
SOLIER, S., ET AL, "The Apoptotic Ring: A Novel Entity with Phosphorylated Histones H2AX and H2B, and Activated DNA Damage Response Kinases", CELL CYCLE, (2009-06-15), vol. 8, no. 12, pages 1853 - 1859 *
STEWART, Z.A., ET AL., "Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-speci c manner", ONCOGENE, (2000-12-15), vol. 20, pages 113 - 124 *
THOMPSON, T., ET AL., "Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis", The Journal of Biological Chemistry, 2004, Vol. 279, No. 51, pages 53015-53022 *
ZHU, Y., ET AL., "Intra-S-Phase Checkpoint Activation by Direct CDK2 Inhibition", MOLECULAR AND CELLULAR BIOLOGY, (2004-06-29), vol. 24, no. 14, pages 6268 - 6277 *

Also Published As

Publication number Publication date
IL236195B (en) 2018-07-31
JP6301915B2 (ja) 2018-03-28
CN104364649A (zh) 2015-02-18
AU2013276950A1 (en) 2015-01-29
ES2660131T3 (es) 2018-03-20
IL236195A0 (en) 2015-01-29
EP2861985A1 (en) 2015-04-22
US20150140123A1 (en) 2015-05-21
WO2013185884A1 (en) 2013-12-19
JP2015521728A (ja) 2015-07-30
CN104364649B (zh) 2017-05-17
CA2876402A1 (en) 2013-12-19
EP2861985B1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
EP2861985B1 (en) Protein expression analyses for identifying genotoxic compounds
Ediriweera et al. In vitro assays and techniques utilized in anticancer drug discovery
JP2024016122A (ja) Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法
US20230126657A1 (en) Compositions and Methods for Identifying and Treating Dystonia Disorders
JP2015006189A (ja) キナーゼ阻害剤のプロファイリング方法
US12013406B2 (en) Methods of detecting anti-folic acid antibodies and uses thereof
JP2012529659A (ja) アルツハイマー病の進行を検出、診断、およびモニターするための方法およびシステム
Trask Jr et al. Assay Development and Case History of a 32K‐Biased Library High‐Content MK2‐EGFP Translocation Screen to Identify p38 Mitogen‐Activated Protein Kinase Inhibitors on the ArrayScan 3.1 Imaging Platform
AU2009313167B2 (en) Use of EEF1A as biomarker for screening of MetAP2 inhibitors
Kaiser et al. Inhibition of EIF-5A prevents apoptosis in human cardiomyocytes after malaria infection
WO2010051882A1 (en) Use of eef1a as biomarker and a method of screening metap2 inhibitors
WO2011009523A1 (en) Eg5 as biomarker in rare thoracic cancer
US20110111980A1 (en) Method for profiling drug compounds
EP4520324A1 (en) Composition comprising a taurine transporter (taut) inhibitor and 5-aminolevulinic acid (5-ala), its use in treating cancer cell tumors, and analysis of the effectiveness of the composition
JP7449589B2 (ja) Ｂｃｌ２ファミリータンパク質標的薬物に対する反応性予測方法
EP2855425A2 (en) Novel phenyl glyoxal probes
Bernsteel et al. In vitro protein kinase activity measurement by flow cytometry
US20030077678A1 (en) Diagnostic kit for schizophrenia
CN108283013B (zh) 骨髓纤维症的诊断和预后辅助及治疗效果监测方法及装置
L Chang et al. Quantification of intracellular proteins and monitoring therapy using flow cytometry
CN101120100A (zh) 通过包括转录因子测定的生物标志分析描绘肿瘤的方法和试剂盒
US9784739B2 (en) Regulatory brain specific cytoplasmic RNAS (BC RNAs) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired